Related Experiment Video
Updated: Aug 11, 2026
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
Published on: October 25, 2011
Mitomycin, ifosfamide, cisplatin for non-small cell lung cancer: an implementation study
T Berghmans1, A P Meert, V Ninane
1Department of Intensive Care Unit and Thoracic Oncology, Institut Jules Bordet, Brussels, Belgium. thierry.berghmans@bordet.be
The MIP regimen (mitomycin, ifosfamide, cisplatin) is effective for non-small cell lung cancer (NSCLC) in hospital settings, matching trial results. Key survival factors include performance status, LDH, early stage, and active smoking.
Area of Science:
- Oncology
- Clinical Pharmacology
Background:
- The MIP regimen (mitomycin, ifosfamide, cisplatin) showed efficacy in non-small cell lung cancer (NSCLC) trials.
- This study evaluated MIP's effectiveness in a broader hospital population.
Purpose of the Study:
- To confirm the efficacy of the MIP regimen in routine NSCLC patient management.
- To assess factors influencing response and survival in a real-world setting.
Main Methods:
- Retrospective analysis of 204 NSCLC patients treated with MIP from 1987-2004.
- Standardized chemotherapy administration, staging, and follow-up for all patients.
Main Results:
- Objective response rates were 36.8% (in trials) and 40.7% (outside trials).
- Stage was the only significant predictor of objective response.
- Survival was influenced by performance status, LDH, early stage, and active smoking.
Conclusions:
- Clinical trial participation did not significantly impact MIP regimen efficacy.
- The MIP regimen is effective in the routine management of NSCLC.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
05:11Construction of An Orthotopic Xenograft Model of Non-Small Cell Lung Cancer Mimicking Disease Progression and Predicting Drug Activities
Published on: May 10, 2024